CDK6 Protein

Migration, Crosslink

📖

CDK6 Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-cdk6-protein

📖 Wiki Page

protein2710 wordssynced 2026-04-02

CDK6 Protein (Cyclin-Dependent Kinase 6)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CDK6 Protein</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CDK6</td>
</tr>
<tr>
<td class="label">Primary activators</td>
<td>D-type cyclins</td>
</tr>
<tr>
<td class="label">Normal function</td>
<td>Cell cycle G1/S</td>
</tr>
<tr>
<td class="label">AD involvement</td>
<td>Cell cycle re-entry</td>
</tr>
<tr>
<td class="label">Therapeutic targeting</td>
<td>CDK4/6 inhibitors</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>

Overview

...

CDK6 Protein (Cyclin-Dependent Kinase 6)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CDK6 Protein</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CDK6</td>
</tr>
<tr>
<td class="label">Primary activators</td>
<td>D-type cyclins</td>
</tr>
<tr>
<td class="label">Normal function</td>
<td>Cell cycle G1/S</td>
</tr>
<tr>
<td class="label">AD involvement</td>
<td>Cell cycle re-entry</td>
</tr>
<tr>
<td class="label">Therapeutic targeting</td>
<td>CDK4/6 inhibitors</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>

Overview

CDK6 (Cyclin-Dependent Kinase 6) is a serine/threonine kinase encoded by the [CDK6](/genes/cdk6) gene that plays critical roles in cell cycle regulation, transcriptional control, and cellular differentiation. While originally characterized for its function in cell proliferation and cancer biology, emerging evidence suggests CDK6 has important roles in the nervous system and contributes to the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@koppensteiner2016][@liu2017].

CDK6 belongs to the CDK (Cyclin-Dependent Kinase) family, which includes closely related kinases CDK4 and CDK6 that function as key regulators of the G1/S cell cycle transition. Unlike their near-homolog CDK4, CDK6 has acquired specialized functions in transcriptional regulation through its ability to phosphorylate transcription factors and chromatin remodeling proteins independent of cell cycle control[@kollmann2011]. This dual functionality—as both a cell cycle regulator and transcriptional co-activator—has implications for understanding how cell cycle dysregulation contributes to neurodegeneration.

Protein Structure and Biochemistry

Domain Architecture

CDK6 is a ~37 kDa protein composed of several distinct structural domains that enable its diverse functions:

Kinase domain: The catalytic core contains the characteristic serine/threonine kinase fold with an ATP-binding pocket in the N-lobe and a catalytic domain in the C-lobe. The activation loop (T-loop) contains key regulatory phosphorylation sites. The kinase domain spans approximately residues 39-303 and contains the conserved motifs characteristic of the CDK family, including the VAIK motif (Val-Ala-Ile-Lys) in subdomain II and the DFG motif (Asp-Phe-Gly) in subdomain VII that define the active conformation[@sherr1999][@zur2011].
Cyclin-binding domain: Located in the N-terminal region (residues 1-35), this domain mediates interaction with D-type cyclins (Cyclin D1, D2, D3), which are required for CDK6 activation. The cyclin-binding interface forms a hydrophobic groove that recognizes the cyclin box motif[@sherr1999].
PSTAIRE helix: The conserved cyclin-binding motif (residues 44-56) undergoes conformational changes upon cyclin binding to activate the kinase. This helix acts as a molecular switch that blocks the active site in the inactive conformation and repositions upon cyclin binding.
C-terminal regulatory region: Contains additional phosphorylation sites that modulate CDK6 activity and subcellular localization, including serine and threonine residues that can be targeted by upstream kinases.

Three-Dimensional Structure

The crystal structure of CDK6 has been solved in both inactive and active conformations:

Inactive conformation (PDB: 1JVP): In the absence of cyclin binding, CDK6 adopts a conformation where the T-loop blocks the substrate-binding site, preventing access to potential substrates.

Active conformation (PDB: 1G3N, 5GAD): Upon cyclin binding, dramatic conformational changes occur:

The PSTAIRE helix repositioning
T-loop stabilization away from the catalytic site
Formation of a functional ATP-binding pocket
Creation of a substrate-binding groove

The CDK6 structure shares high similarity with CDK4, with the main differences in the N-terminal region and the cyclin-binding interface, which explains the differential cyclin preferences between the two kinases.

Regulation of Activity

CDK6 activity is tightly regulated through multiple mechanisms:

Cyclin binding: Association with D-type cyclins is the primary activation mechanism. Cyclin binding induces conformational changes that position the T-loop for activation by upstream kinases. The cyclin-CDK6 complex is further stabilized by phosphorylation at T177[@sherr1999][@zur2011].

Phosphorylation: CDK6 is phosphorylated at multiple sites:

Threonine-177 (T177): Phosphorylation in the activation loop by CAK (CDK-activating kinase) is required for full kinase activity. This phosphorylation is constitutive in growing cells and is reversed by protein phosphatases[@lim2012].
Tyrosine-24 (Y24): Inhibitory phosphorylation that can be reversed by CDKs. This site is targeted by Wee1 and Myt1 kinases.
Serine/Threonine sites: Additional regulatory phosphorylation sites in the C-terminal region.

Cyclin-dependent kinase inhibitors (CKIs): CDK6 activity is negatively regulated by INK4 family proteins (p16^INK4a^, p15^INK4b^, p18^INK4c^, p19^INK4d^), which bind specifically to CDK4 and CDK6 to prevent cyclin D binding. The INK4 proteins fold into ankyrin repeat domains that wedge between the cyclin and CDK components, physically preventing complex formation[@malumbres2009].

Proteolytic degradation: CDK6 protein levels are regulated through ubiquitination and proteasomal degradation. The FBXW7 ubiquitin ligase recognizes phosphorylated CDK6 and targets it for degradation, allowing for rapid turnover and cell cycle transitions.

Normal Function in the Nervous System

Expression in the Brain

CDK6 is expressed throughout the central nervous system, with particularly high levels in regions associated with learning and memory, including the hippocampus and cerebral cortex. In the developing brain, CDK6 plays essential roles in neural progenitor cell proliferation and differentiation[@grossel2006]. During cortical development, CDK6 regulates the transition from proliferative neural progenitor cells to post-mitotic neurons.

Immunohistochemical studies have shown that CDK6 is localized primarily in the nucleus of neurons, with lower levels in glial cells. During embryonic development, CDK6 expression peaks during the period of active neurogenesis and gradually decreases as neurons differentiate. In the adult brain, CDK6 expression remains moderate in the subventricular zone and dentate gyrus of the hippocampus, regions where adult neurogenesis occurs, suggesting continued involvement in neural stem cell regulation.

Cell Cycle Control in Post-Mitotic Neurons

While mature neurons are generally considered post-mitotic, recent research has revealed that cell cycle regulatory proteins including CDK6 have non-canonical functions in differentiated neurons. These include:

Transcriptional regulation: CDK6 can phosphorylate transcription factors including Rb, E2F1, and FOXO proteins to regulate gene expression programs related to neuronal survival and plasticity[@kollmann2011]. Unlike proliferating cells where Rb phosphorylation leads to cell cycle progression, in neurons CDK6-mediated Rb phosphorylation may serve distinct transcriptional regulatory purposes.
Synaptic plasticity: CDK6 activity influences synaptic vesicle trafficking and neurotransmitter release through phosphorylation of synaptic proteins. The presynaptic protein synapsin I is phosphorylated by CDK6, modulating its association with synaptic vesicles and affecting neurotransmitter release dynamics[@gandy2005].
DNA repair: Emerging evidence suggests CDK6 participates in DNA damage response pathways in neurons, which are particularly vulnerable to genomic stress. CDK6 can phosphorylate checkpoint kinases and contribute to cell cycle arrest in response to DNA damage.

The dual functionality of CDK6 in neurons—as both a potential cell cycle driver and a transcriptional co-regulator—has important implications for understanding neurodegeneration. When CDK6 activity becomes dysregulated, these normally separate functions may become coupled inappropriately, leading to aberrant cell cycle re-entry.

Neuroprotective Functions

Under normal physiological conditions, CDK6 exhibits neuroprotective properties:

Stress response: CDK6 phosphorylation of FOXO transcription factors can promote expression of antioxidant and anti-apoptotic genes. FOXO proteins regulate transcription of genes involved in oxidative stress resistance, including superoxide dismutase and catalase[@baker2012].
Metabolic regulation: CDK6 influences glucose metabolism in neurons through transcriptional programs that maintain energy homeostasis. CDK6 can modulate the expression of glucose transporters and metabolic enzymes.
Trophic factor signaling: CDK6 integrates signals from neurotrophins and growth factors to support neuronal survival. Brain-derived neurotrophic factor (BDNF) signaling involves CDK6 activation, linking trophic support to neuronal plasticity and survival.
Calcium homeostasis: CDK6 has been implicated in regulating calcium signaling through modulation of calcium channel expression and function, which is critical for neuronal excitability and signaling.

Role in Alzheimer's Disease

Cell Cycle Re-entry Hypothesis

One of the leading theories explaining neurodegeneration in AD involves the inappropriate re-entry of post-mitotic neurons into the cell cycle[@park2020]. This phenomenon, termed "cell cycle re-entry," is characterized by the re-expression of cell cycle proteins including cyclins, CDKs, and checkpoint regulators. CDK6 plays a central role in this process:

Upregulation in AD brain: Multiple studies have demonstrated increased CDK6 expression and activity in AD-affected brain regions, particularly in the hippocampus and prefrontal cortex[@koppensteiner2016].

Pathogenic mechanisms: Aberrant CDK6 activity contributes to:

Tau hyperphosphorylation through activation of downstream kinases
[Amyloid-beta](/proteins/amyloid-beta)induced toxicity
Neuronal apoptosis
Synaptic dysfunction

Molecular Mechanisms

Tau Phosphorylation

CDK6 contributes to tau pathology through multiple mechanisms:

Direct phosphorylation: CDK6 can phosphorylate tau protein at several sites implicated in AD, including Ser202, Thr205, and Ser396[@liu2017].
Activation of downstream kinases: CDK6 activates other tau kinases including CDK5 through regulatory pathways, creating a cascade of tau phosphorylation.
Interaction with glycogen synthase kinase-3beta (GSK3β): CDK6 can modulate GSK3β activity, another major tau kinase implicated in AD pathogenesis.

Amyloid-Beta Effects

The amyloid cascade hypothesis proposes that amyloid-beta (Aβ) accumulation is the primary trigger of AD pathogenesis. CDK6 interacts with Aβ pathology through multiple interconnected mechanisms:

Aβ-induced CDK6 upregulation: Exposure to oligomeric Aβ stimulates CDK6 expression in neurons through activation of the MAPK and NF-κB signaling pathways. This creates a feed-forward loop where Aβ stimulates CDK6 activity, which in turn promotes further Aβ production through effects on amyloid precursor protein (APP) processing[@koppensteiner2016].
APP processing: CDK6 can influence the amyloidogenic processing of APP by modulating the activity of β-secretase (BACE1) and γ-secretase. Hyperactive CDK6 shifts APP cleavage toward the amyloidogenic pathway, increasing Aβ production.
Synaptic toxicity: CDK6 activation contributes to Aβ-induced synaptic loss through mechanisms involving NMDA receptor dysfunction. CDK6-mediated phosphorylation of NMDA receptor subunits alters receptor trafficking and function, leading to excitatory toxicity.
Oxidative stress: CDK6-mediated pathways amplify oxidative damage in Aβ-exposed neurons. CDK6 can suppress antioxidant defenses while simultaneously increasing reactive oxygen species (ROS) production from mitochondria.
Glial activation: Aβ-induced CDK6 activation in microglia promotes pro-inflammatory cytokine release, creating a neurotoxic inflammatory environment that accelerates neurodegeneration.

Neuronal Apoptosis

CDK6 promotes neuronal death in AD through several interconnected pathways:

p53 phosphorylation: CDK6 can phosphorylate p53 at Ser15, enhancing its transcriptional activity and pro-apoptotic function. Phosphorylated p53 transactivates pro-apoptotic genes including BAX, PUMA, and NOXA[@chen2018].
Mitochondrial dysfunction: CDK6 contributes to mitochondrial fragmentation and dysfunction in AD neurons through regulation of fission proteins (Drp1) and fusion proteins (Mfn1/2, OPA1). Mitochondrial dysfunction leads to ATP depletion and increased ROS production.
Caspase activation: CDK6-mediated pathways lead to activation of executioner caspases (caspase-3, caspase-7) and neuronal apoptosis. The CDK6-p53 axis activates the intrinsic apoptosis pathway.
DNA damage response: Neurons with reactivated CDK6 show signs of DNA damage checkpoint activation, including phosphorylation of Chk1 and Chk2. Persistent checkpoint activation can trigger apoptosis in post-mitotic neurons.
ER stress: CDK6 contributes to endoplasmic reticulum stress in AD, activating the unfolded protein response (UPR) and pro-apoptotic signaling pathways.

Clinical Evidence and Biomarkers

Several studies have investigated CDK6 as a potential biomarker and therapeutic target in AD:

CDK6 expression in CSF: Elevated levels of CDK6 have been detected in the cerebrospinal fluid of AD patients compared to controls, suggesting potential as a diagnostic biomarker.
Genetic variants: Preliminary studies have identified CDK6 genetic variants that may modify AD risk, though validation is needed.
Therapeutic trials: While no CDK4/6 inhibitors have reached clinical trials for AD, several preclinical studies using animal models have shown promise. Human trials for repurposing CDK4/6 inhibitors in AD are anticipated.

Therapeutic Implications

The identification of CDK6 in AD pathogenesis has prompted investigation of CDK6 as a therapeutic target:

CDK4/6 inhibitors: FDA-approved cancer drugs including palbociclib, ribociclib, and abemaciclib have shown promise in preclinical models of AD[@canas2014]. These inhibitors can:

Prevent tau hyperphosphorylation
Reduce Aβ toxicity
Improve cognitive function in animal models

Challenges: CDK4/6 inhibitors have potential side effects including myelosuppression and must be carefully dosed for CNS applications.

Combination approaches: CDK6 inhibition may be most effective when combined with other therapeutic strategies targeting Aβ or tau pathology.

Role in Parkinson's Disease

Evidence for CDK6 Involvement

While less extensively studied than in AD, emerging evidence implicates CDK6 in Parkinson's disease pathogenesis through multiple mechanisms:

α-Synuclein regulation: CDK6 can modulate α-synuclein expression and aggregation through transcriptional mechanisms. CDK6 phosphorylates the α-synuclein promoter region and regulates its transcription. Additionally, CDK6 can phosphorylate α-synuclein itself at Ser129, a post-translational modification that promotes aggregation and is found abundantly in Lewy bodies[@wang2019].

Dopaminergic neuron survival: CDK6 activity affects the survival of dopaminergic neurons in the substantia nigra, the primary cell population lost in PD. Excessive CDK6 activity promotes apoptosis of dopaminergic neurons through mechanisms involving oxidative stress and mitochondrial dysfunction.

Inflammation: CDK6 contributes to neuroinflammatory processes through microglial activation and cytokine production. In PD, activated microglia release pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6, which can damage dopaminergic neurons.

Mitochondrial quality control: CDK6 dysregulation impairs mitophagy, the selective autophagy pathway that removes damaged mitochondria. Impaired mitophagy leads to accumulation of dysfunctional mitochondria and increased oxidative stress in dopaminergic neurons.

Molecular Mechanisms

α-Synuclein phosphorylation: CDK6 can phosphorylate α-synuclein at Ser129, a modification associated with Lewy body formation and disease progression. Phospho-Ser129 α-synuclein is the major form found in Lewy bodies and is considered a pathological marker.
Mitochondrial dysfunction: CDK6 contributes to mitochondrial impairment in PD models through:
Regulation of mitochondrial dynamics (fission/fusion)
Modulation of electron transport chain complex activity
Promotion of mitochondrial permeability transition
Inhibition of mitophagy through mTOR pathway effects
Autophagy dysregulation: CDK6 alters autophagy pathways that are critical for clearing misfolded proteins:
mTOR pathway modulation
ULK1 complex regulation
Autophagosome-lysosome fusion impairment
Oxidative stress: CDK6 promotes oxidative stress through multiple mechanisms:
NADPH oxidase activation
Mitochondrial ROS overproduction
Antioxidant system suppression

Therapeutic Potential

CDK4/6 inhibitors are being explored as disease-modifying therapies for PD:

Neuroprotection: Preclinical studies show CDK6 inhibition protects dopaminergic neurons from various toxic insults including MPTP, 6-OHDA, and α-synuclein overexpression[@wang2019].
α-Synuclein clearance: CDK4/6 inhibition may enhance autophagy-mediated clearance of α-synuclein aggregates. Palbociclib treatment reduces α-synuclein accumulation in cellular and animal models.
Anti-inflammatory effects: CDK4/6 inhibitors reduce microglial activation and pro-inflammatory cytokine production in PD models.
BBB penetration: Among CDK4/6 inhibitors, abemaciclib shows the best brain penetration and is being prioritized for PD therapeutic development.

Comparison with CDK5

CDK6 shares functional overlap with CDK5, another neuronal CDK with well-established roles in neurodegeneration:

Both CDKs contribute to neurodegeneration through distinct but complementary mechanisms, and dual targeting may provide therapeutic benefit[@huang2019].

Therapeutic Targeting

FDA-Approved CDK4/6 Inhibitors

Three CDK4/6 inhibitors are approved for cancer treatment:

Palbociclib (Ibrance): First approved CDK4/6 inhibitor for HR-positive breast cancer. Shows brain penetration and has been tested in AD models.

Ribociclib (Kisqali): Second-generation CDK4/6 inhibitor with improved CNS penetration. Under investigation for neurodegenerative diseases.

Abemaciclib (Verzenio): Unique among CDK4/6 inhibitors for continuous dosing and activity in CNS.

Preclinical Evidence in Neurodegeneration

AD models: CDK4/6 inhibitors reduce tau phosphorylation, improve synaptic function, and enhance cognitive performance in mouse models[@canas2014][@liu2017].
PD models: CDK4/6 inhibition protects dopaminergic neurons and reduces α-synuclein pathology[@wang2019].
Mechanisms: Benefits appear to involve both cell cycle blockade and transcription-independent functions.

Challenges and Considerations

Peripheral effects: CDK4/6 inhibitors cause hematological side effects that may limit dosing.

BBB penetration: Not all CDK4/6 inhibitors cross the blood-brain barrier effectively.

Timing: Optimal intervention window relative to disease stage remains unclear.

Combination therapy: CDK6 inhibition may need to be combined with other disease-modifying approaches.

Interacting Proteins

Cyclin D1/D2/D3: Primary regulatory cyclins that activate CDK6[@sherr1999]
p16^INK4a^: Endogenous CDK6 inhibitor
RB1: Retinoblastoma protein, primary CDK6 substrate
FOXO transcription factors: Transcriptional targets
p53: Pro-apoptotic substrate

Pathway Connections

CDK6 connects to several key neurodegenerative pathways:

Cell cycle pathway: CDK6 → RB phosphorylation → E2F activation → cell cycle progression

Tau phosphorylation cascade: CDK6 → GSK3β activation → tau hyperphosphorylation

Apoptosis pathway: CDK6 → p53 phosphorylation → pro-apoptotic gene expression

Synaptic plasticity: CDK6 → Synapsin phosphorylation → neurotransmitter release

Key Publications

[Malumbres & Barbacci, Cell cycle, CDKs and cancer (2009)](https://doi.org/10.1038/nrc2602)

[Kollmann et al., CDK6 transcriptional regulation (2011)](https://doi.org/10.1016/j.tcb.2011.06.001)

[Koppensteiner et al., Cell cycle dysregulation in AD (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.03.027)

[Liu et al., Targeting CDK6 in AD (2017)](https://doi.org/10.1038/cdd.2017.45)

[Huang et al., CDK5 and CDK6 in neurodegeneration (2019)](https://doi.org/10.3389/fnins.2019.00879)

[Wang et al., CDK6 in Parkinson's disease (2019)](https://doi.org/10.1038/s41531-019-0087-3)

[Park et al., Cell cycle re-entry in AD (2020)](https://doi.org/10.1016/j.pneurobio.2020.101869)

[CDK6 Gene](/genes/cdk6)
[Cell Cycle in Neurodegeneration](/mechanisms/cell-cycle-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Tau Protein](/proteins/tau-protein)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[CDK5 Protein](/proteins/cdk5-protein)

External Resources

[UniProt: Q00534](https://www.uniprot.org/uniprot/Q00534)
[PDB: CDK6 structures](https://www.rcsb.org/structure/5GAD)
[GeneCards: CDK6](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDK6)
[PhosphoSitePlus: CDK6 post-translational modifications](https://www.phosphosite.org/proteinAction.action?id=15368&fromProtein=true)

📖 View canonical wiki page →

Related Entities

CDK6PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-cdk6-protein
kg_node_id	CDK6PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5f24331c623d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cdk6-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CDK6 Protein

CDK6 Protein (Cyclin-Dependent Kinase 6)

Overview

CDK6 Protein (Cyclin-Dependent Kinase 6)

Overview

Protein Structure and Biochemistry

Domain Architecture

Three-Dimensional Structure

Regulation of Activity

Normal Function in the Nervous System

Expression in the Brain

Cell Cycle Control in Post-Mitotic Neurons

Neuroprotective Functions

Role in Alzheimer's Disease

Cell Cycle Re-entry Hypothesis

Molecular Mechanisms

Tau Phosphorylation

Amyloid-Beta Effects

Neuronal Apoptosis

Clinical Evidence and Biomarkers

Therapeutic Implications

Role in Parkinson's Disease

Evidence for CDK6 Involvement

Molecular Mechanisms

Therapeutic Potential

Comparison with CDK5

Therapeutic Targeting

FDA-Approved CDK4/6 Inhibitors

Preclinical Evidence in Neurodegeneration

Challenges and Considerations

Interacting Proteins

Pathway Connections

Key Publications

External Resources

💬 Discussion

📗 Cite This Artifact

CDK6 Protein

CDK6 Protein (Cyclin-Dependent Kinase 6)

Overview

CDK6 Protein (Cyclin-Dependent Kinase 6)

Overview

Protein Structure and Biochemistry

Domain Architecture

Three-Dimensional Structure

Regulation of Activity

Normal Function in the Nervous System

Expression in the Brain

Cell Cycle Control in Post-Mitotic Neurons

Neuroprotective Functions

Role in Alzheimer's Disease

Cell Cycle Re-entry Hypothesis

Molecular Mechanisms

Tau Phosphorylation

Amyloid-Beta Effects

Neuronal Apoptosis

Clinical Evidence and Biomarkers

Therapeutic Implications

Role in Parkinson's Disease

Evidence for CDK6 Involvement

Molecular Mechanisms

Therapeutic Potential

Comparison with CDK5

Therapeutic Targeting

FDA-Approved CDK4/6 Inhibitors

Preclinical Evidence in Neurodegeneration

Challenges and Considerations

Related Proteins and Pathways

Interacting Proteins

Pathway Connections

Key Publications

Related Pages

External Resources

💬 Discussion